Metastatic Melanoma: ctDNA Drops Then Rises During Self-Directed Antiparasitic Use (Case Report 2026)

Metastatic melanoma patients are increasingly exposed to social-media narratives promoting antiparasitic drugs as cancer therapies. A new September 2026 case report published in Frontiers in Oncology by University of Florida oncologists Ricky Cheng and Daniel V. Araujo offers a rare longitudinal look at what actually happens when a patient chooses this path — complete with ctDNA tracking, serial imaging, and an honest discussion of alternative explanations.

The report is significant because it combines real-world biomarker data with clinical observation at a time when patient-directed antiparasitic use is rising. For readers following the broader landscape of ivermectin in oncology research, this case adds a cautionary clinical datapoint rather than a success story.

Table of Contents

• Patient Presentation and Decision
• ctDNA and Imaging Trajectory
• Mutational Burden and Spontaneous Regression
• Clinical Implications
• Frequently Asked Questions

Patient Presentation and Decision

The patient was a 74-year-old man diagnosed with nodular melanoma of the right lateral neck. At staging, he was found to have nodal metastases and hepatic (liver) metastases — stage IV disease. Rather than pursuing guideline-directed therapy, which for metastatic melanoma typically involves checkpoint inhibitors (anti-PD-1, anti-CTLA-4) or targeted BRAF/MEK inhibitors depending on molecular profile, the patient chose lifestyle modifications and self-administered ivermectin and fenbendazole.

The authors do not specify dosing, duration, or source of the drugs — a reflection of the unregulated nature of self-directed use. They note this case arose in the context of growing social-media promotion of antiparasitic repurposing in oncology, a trend that has outpaced clinical evidence. Patients seeking structured dosing information for any repurposed compound can reference the dosing calculator as a starting point for discussion with their oncologist.

ctDNA and Imaging Trajectory

The patient was monitored with serial tumor-informed ctDNA (Signatera assay) and imaging over time. The trajectory was not linear:

The initial decline in ctDNA from 2.04 to 0.18 MTM/mL — an order-of-magnitude drop — was accompanied by imaging showing reduced metabolic activity and stable or smaller lesions without new sites of involvement. This pattern is consistent with either treatment response or spontaneous disease fluctuation. However, both markers subsequently worsened: ctDNA rose to 0.93 MTM/mL and the dominant axillary nodal mass grew in both size and avidity (increased metabolic activity on PET imaging).

Mutational Burden and Spontaneous Regression

The central interpretive challenge of this case lies in the tumor's molecular profile. The melanoma carried a mutational burden of at least 50 mutations per megabase (mutations/Mb), placing it at the extreme upper end of the immunogenic spectrum. Tumors with such ultra-high mutational burden are known to generate abundant neoantigens — abnormal proteins that can trigger spontaneous immune recognition and attack.

Spontaneous immune-mediated regression of metastatic melanoma is a documented, though unpredictable, phenomenon. The authors explicitly state that spontaneous regression is "at least as plausible an explanation as any effect of the patient's interventions." This is not dismissive language; it is a scientifically honest framing that acknowledges the well-established biology of high-burden melanomas while not claiming to prove or disprove any drug effect.

The case also highlights a critical bias in patient-reported narratives: only the initial improvement tends to be shared on social media, while subsequent progression is rarely publicized. The full trajectory — improvement followed by worsening — is essential for balanced interpretation.

Clinical Implications

The authors contextualize their observations within the broader trend of antiparasitic drug repurposing in oncology. They note the absence of clinical trial evidence supporting efficacy for either ivermectin or fenbendazole in melanoma, and they call for safety counseling given documented toxicities of both drugs — including neurotoxicity with ivermectin and hepatotoxicity with fenbendazole, particularly veterinary formulations.

For clinicians, this case underscores several practical points:

• ctDNA can fluctuate independently of treatment; single timepoints are insufficient for conclusions.
• Ultra-high mutational burden melanomas may show spontaneous regression regardless of intervention.
• Social-media success stories are inherently selected for positive early outcomes and rarely report later progression.
• Veterinary-grade antiparasitics carry documented safety risks when used off-label in humans.

The authors do not advocate for or against antiparasitic use; they present data and context, leaving clinical decisions to the patient-physician relationship. This measured approach aligns with the broader mission of evidence-based reporting on fenbendazole and melanoma research.

Frequently Asked Questions

---

Shop Sanare Lab

Lab-tested products referenced in the research above. Links are provided for convenience — always review the label and consult a professional before use.

Disclaimer: Links are informational and for convenience. This site does not provide medical advice and does not endorse any specific vendor. Always verify product quality, labeling, and consult a licensed professional for health decisions.